VisMederi Group
@VisMederi
Followers
299
Following
260
Media
226
Statuses
495
VisMederi Group is a research and qualified services company group operating in the field of Life Sciences and Public Health.
Siena, Italy
Joined July 2014
Emanuele Montomoli (CSO & Founder) and Alessandro Manenti (CDO) are co-authors of a new scientific publication on a Phase II/III clinical study evaluating the immunogenicity, safety, and tolerability of a new SARS-CoV-2 booster vaccine.🔗
0
1
1
VisMederi represented at GVIRF 2025 by our CSO, Emanuele Montomoli. A valuable opportunity to be part of the global dialogue on vaccine research and innovation. 🌍. #VisMederi #GVIRF2025 #VaccineResearch #GlobalHealth.
it.linkedin.com
Emanuele Montomoli, Founder and Chief Scientific Officer at VisMederi, is currently in Rio de Janeiro to attend the 6th Global Vaccine and Immunization Research Forum (GVIRF). This high-level,...
0
2
1
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
505
643
5K
Emanuele Montomoli, VisMederi's Chief Scientific Officer highlights the superior efficacy of the high-dose trivalent flu vaccination in protecting seniors from influenza. 👇.#VisMederi.
0
1
1
The VisMederi Group wishes you a very Merry Christmas and a prosperous New Year!.At VisMederi, public health is our commitment, and happiness is at the heart of everything we do. Thank you for being part of our journey. #MerryChristmas #HappyNewYear #VisMederi
0
0
1
At the 10th IBP BIOSAFETY CONFERENCE , our Unit Manager Adele Boccuto spoke on a crucial topic: "Emerging viral diseases in an era of global change." .As global challenges rise, so does the need for innovative solutions in biosafety. #EmergingDiseases #Biosafety #VisMederi
0
0
0
Prof. Emanuele Montomoli, Founder and CSO of VisMederi participated in the 52° Congresso SIM. He discussed "New Frontiers in Vaccinology", addressing recent advancements and their impact on public health. #Vaccinology #PublicHealth #Microbiology #SIM2024 #VisMederi
0
1
1
VisMederi is prepared to support any research activity and overall vaccine development for the new public health emergency concerning monkeypox. Read the full article here: #PublicHealth #Monkeypox #VaccineDevelopment #ResearchSupport #vismederi.
pubmed.ncbi.nlm.nih.gov
The results of the present study confirm the presence and cross-reactivity of antibodies elicited by vaccinia-based vaccines, which proved able to neutralize the Monkeypox virus in the presence of an...
0
5
5
VisMederi has been successfully qualified by Qualifyze for conducting activities according to GCLP (Good Clinical Laboratory Practices). Both our laboratory facilities have achieved the prestigious SILVER rating! .#VisMederi #Qualifyze #GCLP #SilverRating #LaboratoryExcellence
0
0
3
Emanuele Montomoli (CSO and VisMederi Founder), Alessandro Manenti (CDO), and Silvia Grappi (Project Director) attended the CEPI Centralized Laboratory Network meeting in Rome. #VisMederi #CEPI #Innovation #StandardizedAssays #FutureOutbreaks #HealthScience #RomeMeeting
0
2
4
New paper dissecting different serological approaches, strategies, and challenges to measure the immune response against Bacteria and Bacterial Vaccines. #VisMederi #Immunology #Serology #BacterialVaccines . Read it here:
0
0
0
Older centenarians are more resilient to COVID-19, this is probably associated with the 1918 Spanish Flu pandemic. A plausible conclusion, taken by the paper published by University of Siena, University of Palermo, University of Kent UK and VisMederi.
0
2
4
We are excited to announce our new partnership with the International Vaccine Institute (IVI), an international nonprofit institution committed to vaccine research and development for developing countries. Read here: #VisMederi #IVI #Vaccines #GlobalHealth
0
3
2
Simone Paletti, Chief Financial Officer at VisMederi Group, recently attended a key finance forum in Milan organized by "Comunicazione Italiana. #VisMederiGroup #CorporateFinance #ESGStrategy #MilanFinanceForum2024
0
1
1
VisMederi Group attended the World Vaccine Congress in Washington, D.C., acknowledged as the most significant and longstanding event dedicated to the field of vaccines. #VisMederi #vaccines #VaccineSaveLives #researchanddevelopment.
0
0
0
The USiena Game 2024 brought together bright minds and passionate learners. @unisiena #USienaGame2024 #Innovation #ScienceEducation #VisMederigroup
0
0
0
VisMederi's founder, Emanuele Montomoli, shares insights on how AI is revolutionizing the way vaccines are developed: #VisMederi #HealthcareInnovation #AIinHealthcare #VaccineDevelopment".
sienanews.it
Eli Lilly e Novartis con Isomorphic Labs, Menarini e Insilico Medicine ed ancora Sanofi con Exscentia: nel settore farmaceutico si moltiplicano le multinazionali che decidono di collaborare con...
0
0
3
Our manuscript "#CEPI Centralized Laboratory Network: a qualification analysis" has been published in The Lancet Microbe Online. Read the full manuscript here: #VisMederi #TheLancetMicrobe #VaccineResearch #SARSCoV2 #ScienceInnovation
0
2
4
It's time to say goodbye!.Thank you Celeste for all that you've contributed to our journey. As you embark on your new adventures, we wish you nothing but the best. Good luck! We're confident that you'll achieve great success!. #VisMederi #Vismederigroup
0
0
0
La squadra VisMederi al 37° Incontro WHO a Londra! Emanuele Montomoli ed Elena Gianchecchi hanno dibattuto su importanti progressi nei vaccini antinfluenzali. Orgogliosi di essere al centro dell'innovazione sanitaria globale! .#VisMederiGroup #VaccinoAntinfluenzale #SaluteGlobale
0
0
1
Team VisMederi at the 37th WHO Meeting in London! Emanuele Montomoli & Elena Gianchecchi discussed vital advances in influenza vaccines. Proud to be at the heart of global health innovation! 🌍💉 #VisMederiGroup #InfluenzaVaccine #GlobalHealth #Innovation
0
0
0